New guidelines could make Wegovy available to over 1.2 million people at risk of heart attacks and strokes.
Category: Health
In a landmark decision, the National Health Service (NHS) in England announced that an additional 1.2 million individuals may soon be eligible for the weight loss medication Wegovy (semaglutide). This move, set to take effect in summer 2026, is being hailed as a "win-win" in the fight against obesity and a major turning point in cardiovascular disease management.
Previously, Wegovy was primarily prescribed for obesity and type 2 diabetes, but new guidelines from the National Institute for Health and Care Excellence (NICE) now allow it to be used for those with existing heart and circulatory conditions, regardless of whether weight loss is the primary objective. This change aims to address the pressing health issue of cardiovascular disease, which is a leading cause of death in the UK.
Under the new plan, individuals with a body mass index (BMI) of 27 or higher who have suffered a heart attack, stroke, or peripheral arterial disease will be eligible for the treatment. This approach broadens access significantly compared to previous NHS guidelines, targeting a demographic that faces a heightened risk of subsequent cardiovascular events.
Health experts have welcomed this initiative, emphasizing its potential to transform lives. Naveed Sattar, a professor of cardiometabolic medicine at the University of Glasgow, stated, "We now have medicines that reduce heart attacks, strokes, and peripheral arterial disease and simultaneously lead to meaningful weight loss – which in turn lowers the risk of many weight-related conditions. These treatments also improve patients’ quality of life in a meaningful way, making this a genuine win-win." Sattar highlighted the importance of addressing weight directly for optimal patient outcomes.
Wegovy is administered as a weekly injection and is intended to be used alongside a healthy diet and increased physical activity. It can also be prescribed in conjunction with other medications, such as statins and anti-hypertensives, to help improve cardiovascular health outcomes. This combined approach aims to provide more comprehensive protection against heart disease.
Clinical trials have demonstrated that semaglutide can reduce the risk of serious heart problems by about 20% in overweight individuals with cardiovascular disease. Interestingly, these benefits can manifest even before substantial weight loss occurs, indicating that the drug may exert direct effects on heart health.
Helen Williams, the National Clinical Director for Cardiovascular Disease Prevention at NHS England, remarked that the new treatment option could be life-changing for over a million people at high risk of heart attack and stroke. "We know that people who have already had a heart attack or stroke face a much higher risk of having another. Used alongside a healthy diet and regular exercise, semaglutide could help prevent thousands of future major cardiovascular events and give many people the chance at a longer and healthier life," she said.
The introduction of Wegovy aligns with the NHS's broader 10-Year Health Plan, which aims to help individuals manage long-term conditions, reduce preventable deaths, and alleviate the strain on healthcare resources. Cardiovascular disease places an enormous burden on the NHS, leading to approximately 100,000 hospital admissions each year for heart attacks and an equal number for strokes. Preventing repeat events is a top priority for healthcare providers.
Jack Turner, Deputy Director for Medicines Negotiation at NHS England, emphasized the innovative nature of this treatment. He stated, "Cardiovascular disease is one of the leading causes of preventable death and avoidable health harm, but it’s also one of the areas with the greatest innovation in the form of new pharmaceuticals and health tech. This latest NHS deal for an innovative medicine will enable NHS patients in England to benefit from the latest application of the drug, semaglutide, that is already helping people as a treatment for obesity and type 2 diabetes."
The rollout of Wegovy is expected to occur in phases, allowing the NHS to adapt and scale up the program gradually. This strategy aims to address potential challenges, such as ensuring equitable access across different regions and managing the logistical demands of providing weekly injections to a large patient population.
Juliet Bouverie OBE, CEO of the Stroke Association, expressed her support for the initiative, noting that stroke shares many risk factors with cardiovascular disease, including high blood pressure and obesity. "As stroke survivors live with the worrying threat of future strokes, it’s important they have options to help prevent that from happening, which suit their own circumstances," she said. Bouverie highlighted the need for personalized medical support, emphasizing that each stroke survivor's unique needs should be considered.
Dr. Sonya Babu-Narayan, Clinical Director at the British Heart Foundation, echoed these sentiments, stating, "So-called ‘weight loss drugs’ like semaglutide have proven benefits beyond reducing the number on the scales – they are now considered important medicines for preventing deadly heart attacks and strokes. Today’s guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers."
The decision to broaden access to Wegovy is backed by strong clinical evidence, with large-scale trials involving over 17,000 participants demonstrating a clear reduction in cardiovascular risk among those treated with semaglutide. Participants receiving the drug were significantly less likely to suffer a heart attack, stroke, or cardiovascular death compared to those on a placebo, underscoring the medication’s potential beyond its initial use for obesity and diabetes.
As this new chapter in preventive medicine begins, the NHS aims to shift its focus toward proactive healthcare. By emphasizing prevention rather than merely treating complications, the introduction of Wegovy could significantly alter the management of chronic conditions like heart disease in the future. For millions of patients, this treatment could translate to fewer hospital visits, reduced anxiety about health risks, and an improved quality of life.
With the rollout of Wegovy on the horizon, the NHS is taking a bold step in the fight against cardiovascular disease, potentially saving thousands of lives and reshaping the future of public health in the UK.